{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06120283",
            "orgStudyIdInfo": {
                "id": "BGB-43395-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-506888-34-00",
                    "type": "REGISTRY",
                    "domain": "EU CTIS"
                }
            ],
            "organization": {
                "fullName": "BeiGene",
                "class": "INDUSTRY"
            },
            "briefTitle": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors",
            "officialTitle": "A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "bgb-alone-or-as-part-of-combination-therapies-in-participants-with-breast-cancer-and-other-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-01",
            "studyFirstSubmitQcDate": "2023-11-01",
            "studyFirstPostDateStruct": {
                "date": "2023-11-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BeiGene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Advanced Breast Cancer",
                "Metastatic Breast Cancer",
                "Hormone-receptor-positive Breast Cancer",
                "Hormone Receptor Positive Breast Carcinoma",
                "Hormone Receptor Positive Malignant Neoplasm of Breast",
                "HER2-negative Breast Cancer",
                "Hormone Receptor Positive HER-2 Negative Breast Cancer",
                "Non-small Cell Lung Cancer"
            ],
            "keywords": [
                "breast cancer",
                "advanced solid tumor",
                "advanced breast cancer",
                "hormone receptor positive breast cancer",
                "HER2-negative breast cancer",
                "Hormone Receptor Positive HER-2 Negative Breast Cancer",
                "BGB-43395",
                "non-small cell lung cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 79,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Phase 1a: Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant or letrozole to assess for safety and tolerability.",
                    "interventionNames": [
                        "Drug: BGB-43395",
                        "Drug: Fulvestrant",
                        "Drug: Letrozole"
                    ]
                },
                {
                    "label": "Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Phase 1b: The recommended dose for expansion (RFDE) for BGB-43395 (in combination with fulvestrant or letrozole) from Phase 1a will be evaluated in HR+ breast cancer and selected tumor-specific cohorts.",
                    "interventionNames": [
                        "Drug: BGB-43395",
                        "Drug: Fulvestrant",
                        "Drug: Letrozole"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BGB-43395",
                    "description": "Planned doses administered orally.",
                    "armGroupLabels": [
                        "Dose Escalation",
                        "Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fulvestrant",
                    "description": "Standard dose administered via intramuscular injection.",
                    "armGroupLabels": [
                        "Dose Escalation",
                        "Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Letrozole",
                    "description": "Standard dose administered orally as a tablet.",
                    "armGroupLabels": [
                        "Dose Escalation",
                        "Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395",
                    "description": "MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate of 28%. MAD is defined as the highest dose administered if MTD is not reached.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-43395",
                    "description": "RDFE of BGB-43395 alone or in combination with fulvestrant or letrozole will be determined based upon the MTD or MAD.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1b: Objective Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants who have confirmed complete response (CR) or partial response (PR) assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
                    "timeFrame": "Up to approximately 60 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1a: ORR",
                    "description": "ORR is defined as the percentage of participants who have confirmed CR or PR assessed by the investigator using RECIST v1.1.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1a and 1b: Duration of Response (DOR)",
                    "description": "DOR is defined as the time from the first determination of an overall response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first as assessed by the investigator.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1a and 1b: Time to Response (TTR)",
                    "description": "TTR is defined as the time from the date of the first dose of study drugs to the date of the first determination of objective response by the investigator using RECIST v1.1.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1b: Disease Control Rate (DCR)",
                    "description": "DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease assessed by the investigator using RECIST v1.1.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1b: Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting \u2265 24 weeks.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1b: Progression-Free Survival (PFS)",
                    "description": "PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1b: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments.",
                    "timeFrame": "Up to approximately 60 months"
                },
                {
                    "measure": "Phase 1a: Observed Plasma Maximum Concentration (Cmax) of BGB-43395 and its metabolite",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase 1a: Observed Plasma Trough Concentration (Ctrough) of BGB-43395 and its metabolite",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase 1a: Area under the concentration-time curve (AUC) of BGB-43395 and its metabolite",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase 1a: Half-life (t1/2) of BGB-43395 and its metabolite",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase 1b: Plasma concentrations of BGB-43395 and its metabolite",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 5 Day 1 (each cycle is 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Phase 1a (Dose Escalation) and 1b (Dose Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors associated with dependency on CDK4, including HR+ breast cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer, and others.\n* Phase 1a: Received prior therapy for their condition (if available) and should be refractory to or intolerant of standard-of-care therapies. In regions where approved and available, participants with HR+ breast cancer must have received at least 2 prior lines of treatment including endocrine therapy and a CDK4/6 inhibitor.\n* Phase 1b: Selected tumor cohorts will include HR+/HER2- breast cancer and additional tumor types.\n* Phase 1b: Participants with HR+/HER2- breast cancer enrolled in regions where CDK4/6 inhibitors are approved and available must have received at least one line of therapy for advanced disease including endocrine therapy and a CDK4/6 inhibitor. Participants can have received up to 2 lines of prior cytotoxic chemotherapy for advanced disease.\n* Stable Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1.\n* Female participants with metastatic HR+/HER2- breast cancer must be postmenopausal or receiving ovarian function suppression treatment.\n* Adequate organ function without symptomatic visceral disease.\n\nExclusion Criteria:\n\n* Prior therapy selectively targeting CDK4 (prior CDK4/6 inhibitor therapy is permitted and required in local regions where it is approved and available).\n* Known leptomeningeal disease or uncontrolled, untreated brain metastases.\n* Any malignancy \u2264 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).\n* Uncontrolled diabetes.\n* Infection requiring systemic antibacterial, antifungal, or antiviral therapy \u2264 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection.\n* History of hepatitis B or active hepatitis C infection.\n* Prior allogeneic stem cell transplantation, or organ transplantation.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Director",
                    "role": "CONTACT",
                    "phone": "1.877.828.5568",
                    "email": "clinicaltrials@beigene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "BeiGene",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sarah Cannon Research Institute (Scri) At Health One",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80219",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Duke Cancer Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "James Cancer Hospital and Solove Research Institute",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "The University of Texas Md Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030-4009",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Next Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "Next Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Blacktown Cancer and Haematology Centre",
                    "status": "RECRUITING",
                    "city": "Blacktown",
                    "state": "New South Wales",
                    "zip": "2148",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.76667,
                        "lon": 150.91667
                    }
                },
                {
                    "facility": "Macquarie University",
                    "status": "RECRUITING",
                    "city": "North Ryde",
                    "state": "New South Wales",
                    "zip": "2109",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.79677,
                        "lon": 151.12436
                    }
                },
                {
                    "facility": "Austin Health",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "state": "Victoria",
                    "zip": "3084",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.75,
                        "lon": 145.06667
                    }
                },
                {
                    "facility": "Peter Maccallum Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Centre Eugene Marquis",
                    "status": "RECRUITING",
                    "city": "Rennes",
                    "zip": "35043",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.11198,
                        "lon": -1.67429
                    }
                },
                {
                    "facility": "Institut de Cancerologie de Louest",
                    "status": "RECRUITING",
                    "city": "St Herblain",
                    "zip": "44800",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21765,
                        "lon": -1.64841
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077289",
                    "term": "Letrozole"
                },
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047072",
                    "term": "Aromatase Inhibitors"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M1743",
                    "name": "Letrozole",
                    "asFound": "Cross-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25769",
                    "name": "Aromatase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}